Icahn boosts stake in Amylin Pharmaceuticals to 7.33%

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Amylin Pharmaceuticals, Inc. investors led by Icahn Partners Master Fund LP bought 100,000 shares of the company's stock on Sept. 9 for $19.08 each.

Icahn also exercised 3,172,270 call options on Sept. 11 that were purchased on Sept. 2 and Sept. 3. The exercise price per option was $14.25, according to a schedule 13D filing with the Securities and Exchange Commission.

In total, Icahn and his affiliates beneficially own approximately 10 million shares, or 7.33%, of the San Diego biopharmaceutical company's common stock.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.